Glympse Bio Revenue and Competitors
Estimated Revenue & Valuation
- Glympse Bio's estimated annual revenue is currently $2.8M per year.
- Glympse Bio's estimated revenue per employee is $125,500
- Glympse Bio's total funding is $96M.
Employee Data
- Glympse Bio has 22 Employees.
- Glympse Bio grew their employee count by -4% last year.
Glympse Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Senior Director, Human Resources | Reveal Email/Phone |
4 | Associate Project Manager | Reveal Email/Phone |
5 | Principal Data Scientist | Reveal Email/Phone |
6 | Scientist II, Synthesis & Discovery | Reveal Email/Phone |
Glympse Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $110.3M | 709 | -9% | N/A | N/A |
What Is Glympse Bio?
We are pioneering the development of synthetic biomarkers ￃﾢ￢ﾂﾬ￢ﾀﾜ biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence ￃﾢ￢ﾂﾬ￢ﾀﾜ that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment. Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases ￃﾢ￢ﾂﾬ￢ﾀﾜ a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human bodyￃﾢ￢ﾂﾬ￢ﾄﾢs own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. Itￃﾢ￢ﾂﾬ￢ﾄﾢs the new frontier of liquid biopsy. Our lead indication is in NASH, and our second indication is in Oncology. Our development pipeline is broad, and we have preclinical validation in over 10 diseases.
keywords:N/A
$96M
Total Funding
22
Number of Employees
$2.8M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Glympse Bio News
Satellite Bio lifts off with $110M to fuel development of its implantable ... RELATED: Glympse Bio premieres with $22M series A and plan for...
Glympse Bio, a Cambridge, Mass.-based biotechnology company, closed a $46.7m Series B financing. The round was led by Section 32 and includes new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, as well as existing investors, includin ...
Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse's novel biosensor platform in fibrotic dise ...
By Colin Kellaher Biotechnology startup Glympse Bio Wednesday said it raised $46.7 million in an oversubscribed Series B financing at an undisclosed valuation. Glympse said Bill Maris' Section 32 venture-capital firm led the round, which also included participation from new investors Temasek, ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.2M | 22 | -61% | N/A |
#2 | $18.8M | 22 | -78% | $198.5M |
#3 | $1.5M | 22 | 10% | N/A |
#4 | $2M | 22 | -19% | N/A |
#5 | $2.8M | 22 | 5% | N/A |